Trial Profile
An Open-label Clinical Trial to Compare the Pharmacokinetics of up to 4 Single Oromucosal Doses of 4 Sprays of Sativexin Patients With Treatment Induced Mild, Moderate and Severe Oral Mucositis (Grade 1 - 3 RTOG Oral Mucositis) With Their Pharmacokinetic Profile Pre-treatment (When Mucositis-free)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Cancer pain; Head and neck cancer; Mucositis
- Focus Pharmacokinetics
- Sponsors Jazz Pharmaceuticals Inc
- 12 May 2015 Planned primary completion date changed from 1 Nov 2014 to 1 May 2015, as reported by ClinicalTrials.gov.
- 12 May 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 27 Jan 2014 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.